drugset
drugset / Trial / NCT05506969

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

NCT05506969 ↗

Phase 2 Completed 200 enrolled Dynavax Technologies Corporation United States Department of Defense · collab
RandomizedSequentialDouble-blindPrevention

Summary

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age

Timeline

Start
2022-08-09
Primary completion
2023-10-03
Completion
2024-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject 1018 ISS Unknown — Other
Subject rF1V Vaccine — Other

Indications

pneumonic plague